Mirati Therapeutics shares are trading lower. Bristol Myers Squibb announced it will acquire the company for $58 per share.
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb has announced its intention to acquire Mirati Therapeutics for $58 per share. This news has led to a decrease in Mirati Therapeutics' share price.
October 09, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bristol Myers Squibb has announced its intention to acquire Mirati Therapeutics, potentially impacting its own share price.
The acquisition could potentially impact Bristol Myers Squibb's share price. The impact could be positive if investors view the acquisition as a good strategic move, or negative if they view it as overpriced or risky.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Mirati Therapeutics' share price is trading lower following the announcement of its acquisition by Bristol Myers Squibb.
The acquisition announcement has led to a decrease in Mirati Therapeutics' share price. Investors may be selling off their shares due to the acquisition price being lower than the current trading price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100